ReviewInternational immunopharmacology2010
Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.
Review in International immunopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Cannabis use in Patients With Inflammatory Bowel Disease is Associated With Longer Endoscopic Duration and Endoscopic Inflammation.Crohn's & colitis 360 · 2025Article
- The activation of CB2 enhances bone remodeling in periodontitis.BMC oral health · 2025Article
- Electroacupuncture ameliorates inflammatory pain through CB2 receptor-dependent activation of the AMPK signaling pathway.Chinese medicine · 2024Article
- Cannabinoids and triple-negative breast cancer treatment.Frontiers in immunology · 2024Review
- Cannabinoids in Periodontology: Where Are We Now?Antibiotics (Basel, Switzerland) · 2023Review
- Clinical Epigenomic Explanation of the Epidemiology of Cannabinoid Genotoxicity Manifesting as Transgenerational Teratogenesis, Cancerogenesis and Aging Acceleration.International journal of environmental research and public health · 2023Review
- Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1-aging and epigenomics.Frontiers in psychiatry · 2023Review
- Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies.Intestinal research · 2022Review
- Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours.Frontiers in immunology · 2022Article
- Wonder or evil?: Multifaceted health hazards and health benefits ofSaudi journal of biological sciences · 2021Review
- Article
- Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment.Frontiers in physiology · 2021Review
- Modulation of the Endocannabinoid System Following Central Nervous System Injury.International journal of molecular sciences · 2019Review
- Chronic exercise modulates the cellular immunity and its cannabinoid receptors expression.PloS one · 2019Article
- Endocannabinoid-related compounds in gastrointestinal diseases.Journal of cellular and molecular medicine · 2018Review
- Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds inCannabis and cannabinoid research · 2017Article
- Downstream effects of endocannabinoid on blood cells: implications for health and disease.Cellular and molecular life sciences : CMLS · 2015Review
- Medical marijuana for digestive disorders: high time to prescribe?The American journal of gastroenterology · 2015Review
- Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review.Mediators of inflammation · 2015Review
- Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The active constituents of Cannabis sativa have been used for centuries as recreational drugs and medicinal agents. Today, marijuana is the most prevalent drug of abuse in the United States and, conversely, therapeutic use of marijuana constituents are gaining mainstream clinical and political acceptance. Given the documented contributions of endocannabinoid signaling to a range of physiological systems, including cognitive function, and the control of eating behaviors, it is unsurprising that cannabinoid receptor agonists and antagonists are showing significant clinical potential. In addition to the neuroactive effects of cannabinoids, an emerging body of data suggests that both endogenous and exogenous cannabinoids are potently immunoactive. The central premise of this review article is that the immunological effects of cannabinoids should be considered in the context of each prescribing decision. We present evidence that the immunological effects of cannabinoid receptor agonists and antagonists are highly relevant to the spectrum of disorders for which cannabinoid therapeutics are currently offered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.